Toxicity
Toxicity, nephritis, fatigue
ADVERSE EVENTS, NEPHRITIS, HYPERTENSION
Three patients were initially accrued to dose level 1 (rivoceranib 300 mg daily). These patients did not have any DLT. However, due to AEs of hypertension, fatigue and nephritis observed outside the DLT period requiring dose holds and dose reductions, the dose of rivoceranib was not escalated above 300 mg daily and 2 more patients were accrued to dose level 1.There were no DLTs noted in any of the five patient treated on this phase 1 study. All study participants experienced adverse events related to study therapy as assessed by the treating investigator (Table 
Toxicity profile and safety summary